Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real‐world evidence

AAW has nothing to declare. JIB has received lecture fees from Boehringer Ingelheim, Novo Nordisk and Zealand Pharma and received research support from Novo Nordisk. JTJ has nothing to declare. PLK has nothing to declare. TFD has received lecture fees from AstraZeneca, Boehringer Ingelheim, Medtronic, Novo Nordisk and Sanofi and received research support from AstraZeneca and Novo Nordisk. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70208. The data that support the findings of this study are available from the corresponding author upon reasonable request. Table S1. Baseline characteristics of 96 patients with T2D followed for 1 year after initiation of oral semaglutide. Group 1 (n = 49) consisted of patients up titrated from 3 to 7 mg oral semaglutide. Group 2 (n = 47) consisted of patients up titrated from 3 to 7 or 14 mg. Table S2. Adverse events registered in the electronic medical record of the 96 patients with type 2 diabetes treated with oral semaglutide for a year. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.